vimarsana.com

Page 12 - உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bona UK Expands Retailer Distribution of Bona Antibacterial Hard-Surface Floor Deep Cleaner

Bona UK Expands Retailer Distribution of Bona Antibacterial Hard-Surface Floor Deep Cleaner MILTON KEYNES, U.K., May 10, 2021 (GLOBE NEWSWIRE) Bona (https://www.bona.com/?changed=true) , a global, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, announced expanded distribution of its newly launched Bona Antibacterial Hard-Surface Floor Deep Cleaner (https://www1.bona.com/en-gb/homeowner/news/antibacterial-cleaner/) among retailers in the United Kingdom nationwide including Lakeland, Robert Dyas, Argos, Amazon, and B&Q. Bona Antibacterial Hard-Surface Floor Deep Cleaner is a unique formulation that provides a deep clean for sealed, hard-surface floors including stone, tile, laminate, vinyl and LVT and kills 99.9 percent of bacteria and viruses .

Bona UK Expands Retailer Distribution of Bona Antibacterial

Bona UK Expands Retailer Distribution of Bona Antibacterial Hard-Surface Floor Deep Cleaner Ready-to-Use Formula Kills 99.9% of Bacteria and Viruses  on Sealed Hard-Surface Floors May 10, 2021 04:00 ET | Source: Bona Bona MILTON KEYNES, U.K., May 10, 2021 (GLOBE NEWSWIRE) Bona ®, a global, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, announced expanded distribution of its newly launched Bona Antibacterial Hard-Surface Floor Deep Cleaner among retailers in the United Kingdom nationwide including Lakeland, Robert Dyas, Argos, Amazon, and B&Q. Bona Antibacterial Hard-Surface Floor Deep Cleaner is a unique formulation that provides a deep clean for sealed, hard-surface floors including stone, tile, laminate, vinyl and LVT and kills 99.9 percent of bacteria and viruses .

Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science

Search jobs 06-May-2021 Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb DGAP-News: Evotec SE / Key word(s): Miscellaneous 06.05.2021 / 07:30 beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR Hamburg, Germany, 06 May 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from

Psalms of David Festival Delivers Profound Live Music and Community Experience with HARMAN Professional Solutions

Psalms of David Festival Delivers Profound Live Music and Community Experience with HARMAN Professional Solutions
digitalmedianet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalmedianet.com Daily Mail and Mail on Sunday newspapers.

Evotec AG: Evotec and the GCKD Study Enter into Strategic Collaboration to Build A Unique Molecular Patient Database

Evotec AG: Evotec and the GCKD Study Enter into Strategic Collaboration to Build A Unique Molecular Patient Database PANOMICS AND EVO PANHUNTER PLATFORMS THE GENERATION OF LONGITUDINAL DATA FOR THOUSANDS OF CKD PATIENTS WILL RESULT IN AN UNPRECEDENTED MOLECULAR PATIENT DATABASE THE STRATEGIC COLLABORATION PROVIDES UNIQUE OPPORTUNITIES TO DEEPEN THE UNDERSTANDING OF DISEASE MECHANISMS, PROGRESSION AND POTENTIAL COMPLICATIONS HAMBURG and ERLANGEN, GERMANY / ACCESSWIRE / May 4, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease ( GCKD ) cohort study. Under the agreement, the research team will make use of Evotec s proprietary

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.